Citations

Clear

2416 citation(s) found for "Yu, Jason".

FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs
O’Shaughnessy, Elizabeth, Yasinskaya, Yuliya, Dixon, Cheryl, Higgins, Karen , Reynolds, Kellie, Ampel, Neil M. , Angulo, David, Blair, Janis E. , Catanzaro, Antonino , Galgiani, John N. , Garvey, Edward P., Johnson, Royce H. , Larwood, David J. , Purdie, Rob , Stevens, David A. , Shukla, Sunita J. , Farley, John, Nambiar, Sumathi , Higgins, Karen, Moore, Jason, Reynolds, Kellie, Lewis, Gareth A. , Rex, John H. , Shubitz, Lisa F. , Page, Stephen John

Mayo Clinic

Clinical Infectious Diseases | October 13, 2021 | Volume: 74 | Issue: 11 | Pages: 2061-2066

10.1093/cid/ciab904 | PMID 34651656 Get It

Abstract Coccidioidomycosis is a fungal disease endemic to the southwestern United States, Mexico, and Central and South America. Prevalence rates are increasing steadily, and new endemic areas of Coccidioides are emerging. Standard treatment is often administered for months to decades, and intolerance to medications and treatment failures are common. No new treatments for coccidioidomycosis have been approved in the United States in nearly 40 years. On 5 August 2020, the US Food and Drug Administration convened experts in coccidioidomycosis from academia, industry, patient groups, and other government agencies to discuss the disease landscape and strategies to facilitate product development for treatment of coccidioidomycosis. This article summarizes the key topics concerning drug development for coccidioidomycosis presented by speakers and panelists during the workshop, such as unmet need, trial designs, endpoints, incentives, research and development support, and collaborations to facilitate antifungal drug development.
Acute kidney injury in patients treated with immune checkpoint inhibitors
Short, Samuel , Sise, Meghan E. , Prosek, Jason, Madhavan, Sethu M. , Soler, María José , Ostermann, Marlies , Abudayyeh, Ala , Anand, Shuchi , Motwani, Shveta S. , Murakami, Naoka , Wanchoo, Rimda, Ortiz-Melo, David I. , Rashidi, Arash , Aggarwal, Vikram , Malik, Abhinav , Loew, Sebastian, Carlos, Christopher A., Chang, Wei‐Ting , Beckerman, Pazit , Mithani, Zain, Renaghan, Amanda DeMauro , Seigneux, Sophie de , Campedel, Luca , Shin, Daniel Sanghoon , Rangarajan, Sunil , Deshpande, Priya , Coppock, Gaia, Eijgelsheim, Mark, Lee, Meghan , Husain, Marium , García-Carro, Clara , Bermejo, Sheila , Lumlertgul, Nuttha , Seylanova, Nina , Flanders, Lucy , Isik, Busra , Mamlouk, Omar , García, Pablo , Kaghazchi, Aydin , Khanin, Yuriy, Kansal, Sheru, Wauters, Els , Chandra, Sunandana , Hsu, Raymond K. , Tio, Maria Clarissa , Mothi, Suraj Sarvode, Singh, Harkarandeep , Reynolds, Kerry L. , Cortazar, Frank B. , Leaf, David E. , Salem, Joe‐Elie , Gupta, Shruti , Kitchlu, Abhijat , Lee, Meghan D , Mamlouk, Omar , Lin, Jamie S , Leaf, David E , Murakami, Naoka , Soler, Maria Jose , Salem, Joe-Elie , Hsu, Raymond K , Ostermann, Marlies , Koessler, Thibaud , Gupta, Shruti , Herrmann, Sandra M. , Glezerman, Ilya G , Sprangers, Ben , Malik, A Bilal, Shah, Chintan V , Kitchlu, Abhijat , Seethapathy, Harish Shanthanu , Strohbehn, Ian A. , Owen, Dwight H , Schmidt-Ott, Kai Martin , Schrag, Deborah , Jhaveri, Kenar D.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 10, 2021 | Volume: 9 | Issue: 10 | Pages: e003467

10.1136/jitc-2021-003467 | PMID 34625513 Get It

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. Methods We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI. Results ICPi-AKI occurred at a median of 16 weeks (IQR 8–32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3–10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI. Conclusions Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.
Climbing Up and Down Binding Landscapes through Deep Mutational Scanning of Three Homologous Protein–Protein Complexes
Heyne, Michael , Shirian, Jason , Cohen, Itay , Papo, Niv , Shifman, Julia M. , Radisky, Evette S. , Papo, Niv , Shifman, Julia M , Peleg, Yoav

Mayo Clinic

Journal of the American Chemical Society | October 6, 2021 | Volume: 143 | Issue: 41 | Pages: 17261-17275

10.1021/jacs.1c08707 | PMID 34609866 Get It

V.I.T.A.M. in COVID 19: A Systematic Approach to a Global Pandemic
Yarrarapu, Siva Naga S. , Bansal, Pankaj , Cusick, Austin , Melody, Megan , Moktan, Varun , Rivero, Andrea , Brigham, Tara , Brumble, Lisa , OʼBrien, Jennifer , Lee, Augustine S. , Klaus, Torp, Santos, Christan D. , Rivera, Candido E., Siegel, Jason , Sanghavi, Devang , Brigham, Tara J, Jennifer, J O'brein, Lee, Augustine, Santos, Christan, Rivera, Candido, Brigham, T J , Bansal, Pankaj , Yarrarapu, Siva Naga S , Abia‐Trujillo, David , Rivero, Andrea, Libertin, Claudia R. , Guru, Pramod , Franco, Pablo Moreno

Mayo Clinic

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine | October 5, 2021 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/11795484211047432 | PMID 34629922 Get It

Introduction In the unprecedented era of COVID-19, ongoing research and evolution of evidence has led to ever-changing guidelines for clinical monitoring and therapeutic options. Formulating treatment protocols requires the understanding and application of the evolving research. Objective The primary objective of this study is to present a systematic evidence-based approach to synthesize the necessary data in order to optimize the management of COVID-19. Methods At Mayo Clinic Florida, we developed a multidisciplinary centralized COVID Treatment Review Panel (TRP) of expert pulmonologists, intensivists, infectious disease specialists, anesthesiologists, hematologists, rheumatologists, and hospitalists that in real-time reviews the latest evidence in peer-reviewed journals, the available clinical trials, and help guide the rapid application of therapeutics or interventions to the patient and the bedside provider. Results/Conclusions The multi-disciplinary team approach of synthesizing clinical data and coordinating care is effective in responding to rapidly evolving and changing evidence. Systematic data collection and evidence-based treatment algorithms enable physicians to rapidly translate the current literature to clinical practice, and improve care and outcomes of patients.
Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel
Bhimraj, Adarsh , Morgan, Rebecca L. , Shumaker, Amy Hirsch, Baden, Lindsey R. , Cheng, Vincent Chi‐Chung , Edwards, Kathryn M. , Gandhi, Rajesh T. , Gallagher, Jason C , Wollins, Dana S., Falck–Ytter, Yngve , Morgan, Rebecca L , Muller, William J. , O’Horo, John C. , Shoham, Shmuel

Mayo Clinic

Clinical Infectious Diseases | October 1, 2021 | Volume: 74 | Issue: 9 | Pages: 1691-1695

10.1093/cid/ciab882 | PMID 34668008 Get It

Abstract Despite the challenges of the pandemic, there has been substantial progress with coronavirus disease 2019 (COVID-19) therapies. Pivotal COVID-19 trials like SOLIDARITY, RECOVERY, and ACCT-1 were rapidly conducted and data disseminated to support effective therapies. However, critical shortcomings remain on trial conduct, dissemination and interpretation of study results, and regulatory guidance in pandemic settings. The lessons that we learned have implications for both the current pandemic and future emerging infectious diseases. There is a need for establishing and standardizing clinical meaningful outcomes in therapeutic trials and for targeting defined populations and phenotypes that will most benefit from specific therapies. Standardized processes should be established for rapid and critical data review and dissemination to ensure scientific integrity. Clarity around the evidence standards needed for issuance of both emergency use authorization (EUA) and biologic license application (BLA) should be established and an infrastructure for executing rapid trials in epidemic settings maintained.
Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords
Bhimraj, Adarsh , Morgan, Rebecca L. , Shumaker, Amy Hirsch, Lavergne, Valéry , Baden, Lindsey R. , Edwards, Kathryn M. , Gandhi, Rajesh T. , Gallagher, Jason C , Wollins, Dana S., Falck–Ytter, Yngve , Morgan, Rebecca L , Cheng, Vincent Chi‐Chung , Muller, William J. , O’Horo, John C. , Shoham, Shmuel

Mayo Clinic

Clinical Infectious Diseases | October 1, 2021 | Volume: 74 | Issue: 9 | Pages: 1686-1690

10.1093/cid/ciab880 | PMID 34668010 Get It

Abstract Given the urgent need for treatments during the coronavirus disease 2019 pandemic, the US Food and Drug Administration issued emergency use authorizations (EUAs) for multiple therapies. In several instances, however, these EUAs were issued before sufficient evidence of a given therapy’s efficacy and safety were available, potentially promoting ineffective or even harmful therapies and undermining the generation of definitive evidence. We describe the strengths and weaknesses of the different therapeutic EUAs issued during this pandemic. We also contrast them to the vaccine EUAs and suggest a framework and criteria for an evidence-based, trustworthy, and publicly transparent therapeutic EUA process for future pandemics.
Primary Tumors of the Pituitary Gland: Radiologic-Pathologic Correlation
Shih, Robert , Schroeder, Jason W. , Koeller, Kelly K. , Shih, Robert Y

Mayo Clinic

RadioGraphics | October 1, 2021 | Volume: 41 | Issue: 7 | Pages: 2029-2046

10.1148/rg.2021200203 | PMID 34597177 Get It

The effect of omega-3 fatty acids on a biomarker of head trauma in NCAA football athletes: a multi-site, non-randomized study
Anzalone, Anthony J. , Carbuhn, Aaron F. , Askow, Andrew T. , Stone, Jason D. , Turner, Stephanie M., Hillyer, Lyn M., Luedke, Joel, Oliver, Jonathan M. , Anzalone, Anthony J , Askow, Andrew T , Heileson, Jeffery L. , W.L., David , Jagim, Andrew R.

Mayo Clinic

Journal of the International Society of Sports Nutrition | September 27, 2021 | Volume: 18 | Issue: 1 | Pages: No page available

10.1186/s12970-021-00461-1 | PMID 34579748 Get It

Regional and Temporal Variation of Ventricular and Conduction Tissue Activity During Ventricular Fibrillation in Canines
Tan, Nicholas Y. , Christopoulos, Georgios , Ladas, Thomas P. , Jiang, Zhi , Sugrue, Alan , Tri, Jason , Tolkacheva, Elena G. , Munoz, Freddy Del‐Carpio , McLeod, Christopher J. , Asirvatham, Samuel J. , Sugrue, Alan , Tri, Jason A , Del-Carpio Munoz, Freddy , DeSimone, Christopher V , Asirvatham, Samuel J , McLeod, Christopher J , DeSimone, Christopher V.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 27, 2021 | Volume: 14 | Issue: 10 | Pages: No page available

10.1161/circep.121.010281 | PMID 34665643 Get It

Background: Rigorous study of ventricular fibrillation (VF) is not feasible in humans. The spatiotemporal characteristics of prolonged VF remain undefined, limiting our understanding of this lethal rhythm. Methods: VF was mapped in 4 canines. The endocardial and epicardial left ventricle (LV) and right ventricle (RV) were sequentially mapped at 0 to 15, 15 to 30, 30 to 45, and 45 to 60 minutes post-induction. Ten consecutive beats were used to determine the average cycle length and regularity index of ventricular and His-Purkinje system signals in discrete regions during each time interval. Results: Average VF time was 58±12 minutes. The shortest ventricular cycle length was present in the RV apical region (70±10 msec) at 0 to 15 minutes and at 15 to 30 minutes (89±31 msec) and LV apical region at 45 to 60 minutes (242±163 msec). The His-Purkinje system cycle length was the shortest at the RV outflow tract (75±3 msec) at 0 to 15 minutes, RV inflow and free wall (89±12 msec) at 15 to 30 minutes, LV apical region (83±14 msec) at 30 to 45 minutes, and inferior and inferolateral LV (145±23 msec) at 45 to 60 minutes. Regularity index was the highest in the RV inflow and free wall (78%) at 0 to 15 minutes, RV apical region (86%) at 15 to 30 minutes, LV septum and epicardial anterior RV (80%) at 30 to 45 minutes, and anterior and anterolateral LV (75%) at 45 to 60 minutes. Conclusions: These data suggest significant regional changes in electrical activity throughout VF in canines. A transition of fastest electrical activity from RV to LV apical regions across VF was observed. These novel insights of the temporal and spatial changes of VF merit further evaluation in diseased hearts to assess for reproducibility of findings.
Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease
Keir, Mary , Fuh, Franklin, Ichikawa, Ryan, Acres, Meghan, Hackney, Jason A. , Hulme, Gillian , Carey, Christopher D. , Palmer, Jeremy M. , Jones, Claire , Long, Anna K, Jiang, Jenny , Klabunde, Sha, Mansfield, John , Looney, Cary M., Faubion, William A. , Filby, Andrew , McBride, Jacqueline , Lamb, Christopher A , Keir, Mary E , Palmer, Jeremy , Jones, Claire J , Mansfield, John C , Kirby, John A , McBride, Jacqueline , Lamb, Christopher A , Long, Anna , Kirby, John A.

Mayo Clinic

The Journal of Immunology | September 24, 2021 | Volume: 207 | Issue: 9 | Pages: 2245-2254

10.4049/jimmunol.2100220 | PMID 34561227 Get It

Abstract Targeting interactions between α4β7 integrin and endothelial adhesion molecule MAdCAM-1 to inhibit lymphocyte migration to the gastrointestinal tract is an effective therapy in inflammatory bowel disease (IBD). Following lymphocyte entry into the mucosa, a subset of these cells expresses αEβ7 integrin, which is expressed on proinflammatory lymphocytes, to increase cell retention. The factors governing lymphocyte migration into the intestinal mucosa and αE integrin expression in healthy subjects and IBD patients remain incompletely understood. We evaluated changes in factors involved in lymphocyte migration and differentiation within tissues. Both ileal and colonic tissue from active IBD patients showed upregulation of ICAM-1, VCAM-1, and MAdCAM-1 at the gene and protein levels compared with healthy subjects and/or inactive IBD patients. β1 and β7 integrin expression on circulating lymphocytes was similar across groups. TGF-β1 treatment induced expression of αE on both β7+ and β7− T cells, suggesting that cells entering the mucosa independently of MAdCAM-1/α4β7 can become αEβ7+. ITGAE gene polymorphisms did not alter protein induction following TGF-β1 stimulation. Increased phospho-SMAD3, which is directly downstream of TGF-β, and increased TGF-β–responsive gene expression were observed in the colonic mucosa of IBD patients. Finally, in vitro stimulation experiments showed that baseline β7 expression had little effect on cytokine, chemokine, transcription factor, and effector molecule gene expression in αE+ and αE− T cells. These findings suggest cell migration to the gut mucosa may be altered in IBD and α4β7−, and α4β7+ T cells may upregulate αEβ7 in response to TGF-β once within the gut mucosa.